

Top 20: TAIWAN - Records 1 Percent Growth

08 July 2014 | Analysis | By BioSpectrum Bureau





Taiwan has a 3 percent share in the bioscience market of the Asia-Pacific region.

The top three companies in Taiwan during 2013 were Grape King, Excelsior Medical, and St. Shine Optical.

Most of the companies in the Top 10 list are in the \$100-200 million range.

A few key developments in Taiwan include:

Taiwan based TaiGen Biotechnology collaborated with Russian firm R-Pharm to develop and commercial- ize nemonoxacin (Taigexyn), a novel antibiotic for the treatment of bacterial infections.

Taiwan's Ministry of Health and Welfare ordered removal of 33 drugs prescribed for asthma, hypertension, ulcers from shelves on safety issues.

GE Healthcare installed FlexFactory biomanufacturing platform in Taiwan.

Taiwan based Genovate Biotechnology and ScinoPharm jointly developed oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B

Scientists at the National Health Research Institute discovered genetic markers that can predict the likelihood of surviving pancreatic cancer.

TAIWAN: TOP 20 BIOSCIENCE COMPANIES

		Revenue		
Rank	Company	CY 2013 (\$M)	CY 2012 (\$M)	Change over 2012
1	Grape King	182.7	149.5	22%
2	Excelsior Medical	168.9	178.5	-5%
3	St.Shine Optical	168.8	135.1	25%
4	China Chemical & Pharmaceutical	167.2	160.4	4%
5	ScinoPharm Taiwan	164.4	148.2	11%
6	Orient Europharma	150.8	146.3	3%
7	TTY Biopharm	100.5	130.2	-23%
8	Standard Chemical & Pharmaceutical	98.7	109.4	-10%
9	Rossmax International	92.2	75.5	22%
10	Avita Corporation	91.0	108.7	-16%
11	Hi-Clearance	85.6	77.2	11%
12	Sinphar Pharmaceutical	83.3	67.6	23%
13	Formosa Laboratories	79.9	81.8	-2%
14	Taiyen Biotech	77.7	74.4	4%
15	Apex Medical Corp	65.2	59.8	9%
16	Sharehope Medicine	60.3	59.4	1%
17	Apex Biotechnology Corp	59.1	65.7	-10%
18	Taiwan Liposome Company	51.3	78.0	-34%
19	Bionime	50.4	46.5	8%
20	Maywufa	48.9	69.6	-30%

^{*} Revenue of listed companies only